Lu-PRRT
- Generic Name
- Lu-PRRT
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Phase 2
Terminated
- Conditions
- Gastro-entero-pancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2025-01-13
- Target Recruit Count
- 35
- Registration Number
- NCT02736448
- Locations
- 🇮🇹
Irst Irccs, Meldola, FC, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath